BRAF V600E Mutation-Specific Antibody: A Review

The significance of BRAF mutations in neoplasia was first recognized in 2002 when mutations were discovered in a broad range of cancers. Numerous subsequent studies expanded our understanding of BRAF V600E as a critical diagnostic, prognostic and predictive biomarker in many cancers. Additionally, the advent of small molecule inhibitors of BRAF V600E rendered assessment of BRAF mutation status essential in tumors such as melanoma. In clinical practice, evaluation of BRAF mutation status has routinely been performed by DNA-based assays utilizing polymerase chain reaction (PCR).
Source: Seminars in Diagnostic Pathology - Category: Pathology Authors: Source Type: research